NetworkNewsBreaks – ABcann Global Corp. (TSX.V:
Post# of 111
(Total Views: 273)
Posted On: 10/17/2017 6:53:02 PM
NetworkNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names Paul Lucas as New Board Chair
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Paul Lucas as its new independent chair following founder Ken Clement’s decision to step down from the position. Clement will continue to serve as a member of the company’s board of directors. “Ken’s visionary leadership has given ABcann a great foundation to build upon and we appreciate his years of dedicated service and contributions,” Paul Lucas stated in the news release. “Having him maintain his position on the Board will help the Company maintain continuity of leadership and historical knowledge. I am thrilled to take on the Chair position as we enter the next phase in our evolution.” Lucas brings decades of pharmaceutical industry experience to the ABcann board, having previously served as president and CEO of GlaxoSmithKline Canada from 1994 to 2012. This morning’s update follows last month’s appointment of Barry Fishman as the company’s new CEO. ABcann notes that, together, these appointments “represent important steps in the Company’s enhancement of its operational oversight and corporate governance standards.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Paul Lucas as its new independent chair following founder Ken Clement’s decision to step down from the position. Clement will continue to serve as a member of the company’s board of directors. “Ken’s visionary leadership has given ABcann a great foundation to build upon and we appreciate his years of dedicated service and contributions,” Paul Lucas stated in the news release. “Having him maintain his position on the Board will help the Company maintain continuity of leadership and historical knowledge. I am thrilled to take on the Chair position as we enter the next phase in our evolution.” Lucas brings decades of pharmaceutical industry experience to the ABcann board, having previously served as president and CEO of GlaxoSmithKline Canada from 1994 to 2012. This morning’s update follows last month’s appointment of Barry Fishman as the company’s new CEO. ABcann notes that, together, these appointments “represent important steps in the Company’s enhancement of its operational oversight and corporate governance standards.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)